Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

EULAR 2012: Does Arthritis Start in the Gut?

Thomas R. Collins  |  Issue: August 2012  |  August 8, 2012

In the colon, knocking out IL-10 in the FOXP3 population gives rise to severe inflammation in mice.

It also appears to be just as important in humans. Researchers at Erasmus found that a girl with severe enterocolitis had a mutation within the IL-10 receptor alpha gene. Within samples of her dendritic cells, tumor necrosis factor and IL-6 were not downregulated as in the healthy control cells.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

It was also found that IL-10 drastically reduces interferon gamma and IL-17 in the healthy cells, but not in the patient’s cells.

“IL-10 signaling is critical to maintain tolerance…in the human colon,” Dr. Samsom said. She said this could help lead to new insights into the control of TH1 and TH17 cells, which could lead to better-tailored treatments.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A Bigger Role for Bacteria?

John Carter, MD, associate professor and chief of the rheumatology division at the University of South Florida in Tampa, said evidence is emerging that bacteria’s role in reactive arthritis—and even undifferentiated spondylarthropathy in general—might be bigger than researchers have thought.

“One [type of] bacteria can cause a classic triad of symptoms in a certain patient and incomplete or a complete absence of this classic triad of symptoms in another,” he said. “Some patients will have spontaneous remission, some patients will develop chronic disease, all from the same bacteria. So, clearly this is a little more complex than originally thought.”

Ocular serovars might play a big part in Chlamydia-based reactive arthritis, he said. It’s been the prevailing view that the genital serovars were the cause of reactive arthritis because the infection is passed genitally but, “it’s important to remember that very rarely you can actually pass the ocular serovars genitally.”

Researchers at Wayne State University and the University of South Florida analyzed serovars of 36 patients with polymerase chain reaction–confirmed synovial Chlamydia trachomatis and found that they were all ocular serovars, with no genital serovars.1

Dr. Carter noted that there are genetic differences between ocular and genital serovars that might explain ocular serovars’ role in causing arthritis.

“If you think about the clinical symptoms of reactive arthritis, often times you have eye involvement, so perhaps this goes a long way in explaining some of the clinical features,” Dr. Carter said.

These recent discoveries “challenge the notion that these bacteria simply trigger an autoimmune response and do not play a role in disease maintenance,” he says. “And it suggests that perhaps too much emphasis has been placed on the host in terms of disease genesis and maintenance” in post-Chlamydial reactive arthritis.

Page: 1 2 3 | Single Page
Share: 

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting ReportsResearch Rheum Tagged with:EULARgut microbiomeInternationalReactive arthritisResearch

Related Articles

    Reactive Arthritis

    October 1, 2010

    Back to the Future

    Watch Those Eyes

    December 1, 2007

    What you need to know about Uveitis in Rheumatic Diseases

    The Microbiome

    November 1, 2011

    A voyage to (our inner) Lilliput

    Treatment Patterns and Trends for Spondylarthropathies

    April 6, 2012

    Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences